StromaOS began in November 2025 with one conviction: that AI will not enter pharmaceutical decision-making through better models, but through systems that can prove what they did. Everything here follows from that.
Regulated scientific work should be able to move at the speed of the question without giving up the record that defends it. Today those two things trade against each other, and the trade is accepted as a law of nature. It is not one - it is an architectural choice that nobody revisited.
Evidence demand is not steady. It spikes at submission, at signal, at a payer challenge. A workforce that can only be scaled by hiring cannot answer that shape of demand, and the gap is absorbed by contract spend and postponed work. We think that gap closes.
None of these is new on its own. Together, and in the same eighteen months, they change what a sponsor can defer.
Cost-cutting at the agencies pushes work back onto sponsors while review expectations hold. Submission overhead becomes the thing worth removing, and platforms that reduce it without weakening the record win the contract.
Formulary and HTA decisions increasingly turn on evidence generated outside the trial. A sponsor without an integrated RWE and HEOR pipeline arrives at those conversations with a weaker case than the science deserves.
Almost none has governed AI infrastructure to execute it. The strategy exists, the budget exists, and the thing the strategy would run on does not - which is why so many programs stall between the pilot and the process.
Changes in compliance expectation have forced renegotiation of long-standing platform agreements. Sponsors who had not planned to evaluate alternatives are evaluating them, and the switching question is live in a way it has not been for a decade.
Coming revisions to evidence and safety guidance assume a traceable line from signal to submitted statement. Most platforms can produce that line only by rebuilding it afterwards, which is the thing an inspector is least willing to accept.
Each pressure resolves to the same requirement: be able to show what happened, why, under whose authority, and what was refused. That is not a reporting feature. It decides how the system is built.
This is not a criticism of the products. Each was built well for the problem it was built for. The difficulty is that none of those problems was governed AI execution, and the gap shows in the architecture rather than the feature list.
Reporting arrives as an afterthought on top of a system of record. Licensing is monolithic, so you pay for modules you never open. AI is added after acquisition rather than designed in, which means it cannot see across the suite. Implementations run in years, not quarters, and on-premise heritage makes the cloud offering a rebadged virtual machine.
Each tool is excellent within its boundary and defines its own vocabulary - so patient means something slightly different in each one, and nothing reconciles them. Compliance burden multiplies with every tool added, integration maintenance becomes a standing job, and safety cannot see trial context because nothing connects them.
Vertical by design, so each solves a slice and leaves the seams. Aggregate data models mean your data improves a shared model. Analytics improve without a workflow layer underneath, so you get better dashboards rather than governed execution - and export is a support ticket rather than a right.
Three properties that no staffing model and no analytics platform can hold at the same time. That combination is the product, and it is the reason the company exists.
Run dozens of parallel studies at the crunch and a fraction of that between them. No headcount plan, no recruiting cycle, no ramp - and no idle cost carried through the quiet quarter.
Fleet memory compounds. The system learns your programs, your definitions and your standards, and it does not leave. Your twentieth study begins with everything the first nineteen established.
The Evidence Data Trace is produced at execution time, not reconstructed afterwards. Every method version, every control evaluated, every checkpoint and every refusal, recorded as it happens.
The arguments that led here were published before the platform existed, and they are on this site unchanged. The design partner program is in selection: additional production Fleet configurations are being co-designed by function with a small number of sponsors and CROs.
The evidence record uses an open, queryable schema and can be read without the platform that produced it. In three of the four deployment postures, execution never leaves your boundary. That is a deliberate architectural answer to a fair question about any young vendor.
The most useful first conversation starts with one function where expert time is being consumed by repeatable work, and looks at what a governed Fleet would actually change.